Ticker > Company >

Mankind Pharma share price

Mankind Pharma Ltd.

NSE: MANKIND BSE: 543904 SECTOR: Pharmaceuticals & Drugs  147k   442   109

2379.00
-2.95 (-0.12%)
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 2385.05

Today's Low

₹ 2342.7

52 Week High

₹ 3050

52 Week Low

₹ 1910.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

98188.17 Cr.

Enterprise Value

97427.15 Cr.

No. of Shares

41.27 Cr.

P/E

52.11

P/B

6.71

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  354.72

CASH

761.01 Cr.

DEBT

0 Cr.

Promoter Holding

72.7 %

EPS (TTM)

₹  45.65

Sales Growth

14%

ROE

20.98 %

ROCE

26.13%

Profit Growth

46.08 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Mankind Pharma Ltd.

Moxikind Mahacef Zenflox Cefakind Telmikind Amlokind Zolahart Overzyme Pantakind Ranidom Asthakind Combihale Nurokind Nurokind Plus Nurokind Gold Health OK Dynaglipt Glimestar Glykind-M Voglistar Unwanted-21 Days Prega News AcneStar Ring-Out Daffy Codistar Clonafit Manforce Epic Health OK Unwanted-72 AcneStar Kabz End Ring-Out Safe Kind Kaloree-1 Heal-O-Kind Calsimust Gel Multistar Liquid Calcimust Strong Liquid Nurokind-Plus Vet Injection Enerdyna Liquid Totavit Strong Powder Ceftiforce Injection Enrostrong

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14%
3 Year18.82%
5 Year19.33%

Profit Growth

1 Year46.08%
3 Year18.91%
5 Year28.82%

ROE%

1 Year20.98%
3 Year21.02%
5 Year23.49%

ROCE %

1 Year26.13%
3 Year26.39%
5 Year30.06%

Debt/Equity

0

Price to Cash Flow

49.52

Interest Cover Ratio

150.8347

CFO/PAT (5 Yr. Avg.)

1.00656514579922

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 72.70 0.00
Dec 2024 72.71 0.00
Sep 2024 74.87 0.00
Jun 2024 74.87 0.00
Mar 2024 74.88 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 18.9145381743531% for the Past 3 years.
  • The company has shown a good revenue growth of 18.817846034388% for the Past 3 years.
  • Company has been maintaining healthy ROE of 21.0175715340708% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.3926676451921% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 150.8347.
  • The Company has been maintaining an effective average operating margins of 23.3530260459624% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -40.1079 days.
  • Company has a healthy liquidity position with current ratio of 3.4441.
  • The company has a good cash flow management; CFO/PAT stands at 1.00656514579922.
  • The company has a high promoter holding of 72.7%.

 Limitations

  • The company is trading at a high PE of 52.11.
  • The company is trading at a high EV/EBITDA of 34.4439.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 2007.47 2403.26 2529.74 2396.57 2126.59
Total Expenditure 1481.69 1831.06 1777.71 1655.64 1649.67
Operating Profit 525.78 572.2 752.03 740.93 476.92
Other Income 84.96 94.83 105.76 69.82 219.32
Interest 4.29 6.26 1.92 199.47 162.25
Depreciation 86.62 83.4 85.42 87.03 105.24
Exceptional Items 0 0 0 0 0
Profit Before Tax 519.83 577.37 770.45 524.25 428.75
Tax 75.39 93.12 168.01 107.87 46.29
Profit After Tax 444.44 484.25 602.44 416.38 382.46
Adjusted EPS (Rs) 11.09 12.09 15.04 10.09 9.27

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 4794.41 5523.18 7486.22 8127.15 9264.81
Total Expenditure 3550.47 4151.05 5647.73 6429.29 6939.19
Operating Profit 1243.94 1372.13 1838.49 1697.86 2325.61
Other Income 93.85 154.5 203.81 162.78 266.64
Interest 11.1 8.23 47.54 28.23 15.08
Depreciation 61.77 78.19 123.33 269.58 317.61
Exceptional Items 0 0 0 0 0
Profit Before Tax 1264.92 1440.21 1871.44 1562.84 2259.57
Tax 306.7 355.83 482.01 314.58 436.16
Net Profit 958.23 1084.37 1389.42 1248.26 1823.41
Adjusted EPS (Rs.) 23.92 27.07 34.68 31.16 45.52

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 40.06 40.06 40.06 40.06 40.06
Total Reserves 3611.39 4694.21 6500.39 7743.85 9583.75
Borrowings 0 0 0 0 0
Other N/C liabilities 42.84 54.11 126.98 168.12 200.54
Current liabilities 815.77 1078.91 2271.27 1419.09 1593.36
Total Liabilities 4510.06 5867.29 8938.7 9371.12 11417.71
Assets
Net Block 939.25 981.95 2921.3 3136.89 3399.07
Capital WIP 143.93 165.51 355.28 437.83 112.88
Intangible WIP 3.69 0.06 31.28 56.95 74.7
Investments 1389.51 1500.86 1657.08 2040.76 2190.62
Loans & Advances 77.6 115.59 146.3 148.86 137.64
Other N/C Assets 10.17 16.04 14.45 36.1 15.08
Current Assets 1945.9 3087.28 3813.01 3513.72 5487.71
Total Assets 4510.06 5867.29 8938.7 9371.12 11417.71
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1264.92 1440.21 1871.44 1562.84 2259.57
Adjustment 137.23 96.74 -4.16 227 161.91
Changes in Assets & Liabilities -168.42 -156.19 -585.61 294.21 -40.95
Tax Paid -274.12 -397.38 -460.22 -285.06 -397.55
Operating Cash Flow 959.61 983.38 821.44 1798.99 1982.97
Investing Cash Flow -395.68 -1127.16 -1360.27 -1040.61 -1919.22
Financing Cash Flow -558.91 88.87 578.63 -710.41 -8.68
Net Cash Flow 5.02 -54.91 39.81 47.96 55.07

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 74.88 74.87 74.87 72.71 72.70
arjun juneja 2.04 2.04 2.04 1.98 1.98
chanakya juneja 0.97 0.97 0.97 0.94 0.94
eklavya juneja 0.97 0.97 0.97 0.94 0.94
mishka arora 0.74 0.74 0.74 0.72 0.72
poonam juneja 2.64 2.64 2.64 2.56 2.56
prem sheetal family trust... 15.42 15.41 15.41 14.97 14.97
puja juneja 2.88 2.88 2.88 2.80 2.80
rajeev juneja 1.62 1.62 1.62 1.58 1.58
rajeev juneja family trus... 19.95 19.95 19.95 19.37 19.37
ramesh juneja 1.71 1.71 1.71 1.66 1.66
ramesh juneja family trus... 20.81 20.81 20.80 20.20 20.20
ria chopra juneja 0.32 0.32 0.32 0.31 0.31
sheetal arora 4.81 4.81 4.81 4.67 4.67
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 25.12 25.13 25.13 27.29 27.30
axis mutual fund trustee ... - 1.28 - 1.06 1.29
government pension fund g... - - 1.11 1.54 1.52
nps trust- a/c sbi pensio... - - - - 1.02
sbi large & midcap fund - 1.50 - - 1.58
sbi life insurance co. lt... - - - - 1.05
sbi nifty 500 index fund - - - 1.67 -
sbi nifty midcap 150 inde... 1.52 - 1.49 - -
tata aia life insurance c... - - 1.08 - -
hema cipef (i) limited 2.22 1.62 - - -
icici prudential mutual f... - 1.00 - - -
axis mutual fund trustee ... 1.54 - - - -
icici prudential mutual f... 1.60 - - - -

Annual Reports

Title Action
Annual Report 2024
Annual Report 2023

Ratings & Research Reports

TYPE AGENCY ACTION
Credit CARE
Credit ICRA
Credit ICRA
Credit CRISIL
TYPE AGENCY ACTION
Research Geojit

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY25
Concall Q4FY24
Concall Q3FY25
Concall Q3FY24
Concall Q2FY24
Concall Q1FY25
TYPE QUARTER ACTION
Presentation Q4FY24
Presentation Q4FY23
Presentation Q3FY25
Presentation Q3FY24
Presentation Q2FY24
Presentation Q1FY25
Presentation Q1FY25
Presentation Q1FY25
Presentation H1FY24

Company News

Mankind Pharma Stock Price Analysis and Quick Research Report. Is Mankind Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Mankind Pharma and its performance over the period of time. Mankind Pharma stock price today is Rs 2381.3.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Mankind Pharma cash from the operating activity was Rs 1982.9732 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Mankind Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Mankind Pharma , the EPS growth was 46.0765 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Mankind Pharma has OPM of 25.1015927548557 % which is a good sign for profitability.
     
  • ROE: Mankind Pharma have a healthy ROE of 20.9775 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Mankind Pharma is Rs 2381.3. One can use valuation calculators of ticker to know if Mankind Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Mankind Pharma
X